“…The blood clotting test was adapted from Shih et al [18]. Dressings were placed into polypropylene tubes, and prewarmed to 37 C. Citrated whole blood (0.2 mL) was then dispensed onto the dressings, and 20 mL of 0.2 M CaCl 2 solution added to start coagulation.…”
“…The blood clotting test was adapted from Shih et al [18]. Dressings were placed into polypropylene tubes, and prewarmed to 37 C. Citrated whole blood (0.2 mL) was then dispensed onto the dressings, and 20 mL of 0.2 M CaCl 2 solution added to start coagulation.…”
“…The blood clotting assay was performed based on the procedure described in literature [32,33]. Blood (5 ml) was taken from healthy volunteers and 10% acid citrate dextrose (ACD) was added as anticoagulant.…”
“…21 Clear separation of the upper plasma layer from the red blood cells was observed. The top one milliliter of the plasma layer was retrieved and designated as PRP.…”
Antibody-conjugated surfaces are being studied for cardiovascular implant applications to capture endothelial progenitor cells and promote endothelialization. However, despite the large amount of literature on endothelial progenitor cell capture efficiency, little effort has been made to understand acute blood responses to the modified surfaces. We hypothesize that CD34 antibody conjugation passivates surfaces against procoagulatory events, and thus improves hemocompatibility. To test this hypothesis, we subjected the modified films to hemocompatibility tests to evaluate contact activation, platelet adhesion and activation, as well as whole blood clotting response to the films. Here, we demonstrate the alteration of blood responses due to polyacrylic acid (PAAc) engraftment and subsequent antibody conjugation on biaxially stretched polycaprolactone (PCL) films. Compared to PCL, PAAc-engrafted PCL (PCL-PAAc) and CD34-antibody-conjugated films (PCL-PAAC-CD34) resulted in a four- to ninefold (p < 0.001) reduced platelet activation. PCL-PAAc, however, resulted in an increased contact activation on thromboelastography, and a poorer blood compatibility index assay (43.4% +/- 2.3% vs. 60.9% +/- 2.5%, p < 0.05). PCL-PAAC-CD34, on the other hand, resulted in delayed clot formation (r = 19.3 +/- 1.5, k = 6.8 +/- 0.6 min) and reduced platelet adhesion and activation, and yielded the highest blood compatibility index score, indicating least thrombogenicity (69.3% +/- 3.2%). Our results suggest that CD34 antibody conjugation significantly improved the hemocompatibility of PAAc-conjugated PCL.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.